Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Syndrome Clear all
Completed Not applicable Interventional Results available

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

NCT00514852
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Not applicable Interventional

Feasibility of IPL Combined With RF for Treatment of DED Due to MGD

NCT05487547
View directory record Official record
Conditions
Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
IPL_RF_MGX
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New York, New York • Harrisburg, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Phase 2 Interventional

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT07179055
View directory record Official record
Conditions
Dry Eye
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Newport Beach, California • Andover, Massachusetts • Shelby, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
CFZ533, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

NCT04630158
View directory record Official record
Conditions
Chronic Ocular Pain
Interventions
SAF312 Placebo, SAF312
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Mission Hills, California • Newport Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 21, 2026, 10:16 AM EDT
Terminated Phase 4 Interventional Results available

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

NCT00553735
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine A 0.05%, Arificial Tear
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04201574
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ALY688 0.1%, ALY688 0.4%, Vehicle
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Phase 4 Interventional

TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED)

NCT07732010
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
TRYPTYR (Acoltremon ophthalmic solution 0.003%)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 4 Interventional

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

NCT00520260
View directory record Official record
Conditions
Dry Eye Disease, Ocular Comfort
Interventions
bromfenac, ketorolac
Drug
Lead sponsor
Florida Eye Microsurgical Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Oct 21, 2026, 10:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point of Care Testing of Inflammatory Markers in Tears

NCT02315079
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Eye inflammation, Without eye inflammation
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 21, 2026, 10:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucin Levels in Dry Eye and Normal Populations

NCT05911555
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 10:16 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 21, 2026, 10:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408
View directory record Official record
Conditions
Sjögren's Syndrome (SS)
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
41
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Ianalumab (VAY736), Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
32
States / cities
Fullerton, California • La Palma, California • Van Nuys, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Not applicable Interventional Results available

Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

NCT04795752
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction

NCT06483750
View directory record Official record
Conditions
Dry Eye Disease, Meibomian Gland Dysfunction, Cataract Senile, Dry Eye Syndromes
Interventions
Systane iLux Treatment
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Not applicable Interventional Results available

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal Neurostimulator
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Artesia, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 21, 2026, 10:16 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Sjogrens Syndrome Measured by Ultrasound

NCT03411850
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Orencia, Placebo
Biological · Other
Lead sponsor
Arthritis & Rheumatism Associates, P.C.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 21, 2026, 10:16 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort

NCT04163328
View directory record Official record
Conditions
Dry Eye, Contact Lens Complication
Interventions
HydroEye®
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 1Phase 2 Interventional

Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

NCT03226444
View directory record Official record
Conditions
Primary Sjögren Syndrome, Dry Eye
Interventions
0.005% Lacripep, 0.01% Lacripep, Placebo
Drug
Lead sponsor
TearSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Azusa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Total30 Sphere Contact Lenses

NCT05183022
View directory record Official record
Conditions
Contact Lens Complication, Dry Eye
Interventions
Total30 Sphere Contact Lenses
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome

NCT01632137
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Rebamipide 2% ophthalmic suspension, Placebo (vehicle)
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Artesia, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

NCT03226769
View directory record Official record
Conditions
Meibomian Glands, Dry Eye Syndromes
Interventions
TrueTear™, Thermalon Dry Eye Compress
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 21, 2026, 10:16 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

NCT06329661
View directory record Official record
Conditions
Dry Eye Disease, Endothelial Cell
Interventions
Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Newport Beach, California • Torrance, California • Garner, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 10:16 AM EDT